Loading organizations...

Hey Jane is a technology company.
Hey Jane is a virtual clinic providing accessible reproductive and sexual health services. Its core offering is telehealth-based medication abortion, complemented by birth control, emergency contraception, and treatments for common vaginal infections. The platform connects patients with licensed clinicians, delivering discreet, evidence-based care across numerous states.
Co-founded in 2021 by Kiki Freedman, Hey Jane originated from the critical need for accessible abortion care amidst increasing restrictions. The company capitalized on the shift to telehealth for abortion pill prescriptions, solidified by the FDA's permanent lifting of in-person dispensing requirements. This established a new virtual pathway for reproductive health services.
Hey Jane serves individuals seeking confidential, affordable reproductive healthcare. The company’s mission is to ensure universal access to safe, supportive reproductive and sexual health services. Through its innovative model, Hey Jane removes barriers and expands evidence-based care options, envisioning a future where essential services are readily available to all.
Hey Jane has raised $18.3M across 4 funding rounds.
Hey Jane has raised $18.3M in total across 4 funding rounds.
Hey Jane has raised $18.3M in total across 4 funding rounds.
Hey Jane's investors include 37 Angels, Amboy Street Ventures, G9 Ventures, Koa Labs, Moving Capital, Portfolia, Social Starts, The Helm, Ulu Ventures, FourSight Capital Partners, Gaingels, Awesome People Ventures.
Hey Jane is a New York-based telehealth company founded in 2019 (with operations launching in 2021) that provides virtual medication abortion services, delivering FDA-approved abortion pills directly to patients' homes in 23 U.S. states where legal.[3][5] It serves over 100,000 patients seeking discreet, affordable reproductive care, offering consultations within one day, sliding-scale pricing as low as $0 with insurance, and additional services like birth control, emergency contraception, and infection treatments.[3][5][7] The company solves access barriers amid clinic closures and restrictions post-Roe v. Wade by enabling telemedicine without in-person visits, at less than half the average in-clinic cost, while ensuring HIPAA-compliant, evidence-based care supported by an in-house clinical team.[1][3][4][6]
Hey Jane has demonstrated strong growth, raising nearly $10 million in venture capital by early 2023 and expanding from abortion pills to holistic reproductive health, with high patient satisfaction (4.94★ average rating).[2][3] Its model emphasizes privacy, speed, and support, including 24/7 nursing lines and partnerships with abortion funds.[5]
Hey Jane was co-founded in 2019 by Kaitlin (Kiki) Freedman, who serves as CEO, and Gaby Izarra, both with prior experience at Silicon Valley firms like Uber, Webflow, and Autodesk.[1][4] The idea emerged amid growing U.S. abortion restrictions and clinic closures, launching fully in January 2021 as one of the first legal telemedicine providers for medication abortion.[3][5] Early traction accelerated post-Roe v. Wade in 2022, serving nearly 10,000 patients initially and scaling to over 20,000 by January 2023, while raising $3.6 million (later nearly $10 million) in funding.[1][2]
Pivotal moments include rapid expansion to 23 states, independent certifications from the National Abortion Federation and LegitScript, and research validating its safety and effectiveness.[3][5][6] By 2025, it had reached 100,000+ patients and begun supporting studies on telehealth abortion and Medicaid access.[3]
Hey Jane rides the telemedicine boom in reproductive health, accelerated by Roe v. Wade's 2022 overturn, which spiked demand for mail-order abortion amid state bans and clinic strains.[1][2][6] Its timing leverages FDA allowances for telehealth abortion, positioning it as a leader in virtual clinics—scaling access where 1 in 5 U.S. women face barriers.[3][6]
Market forces like insurance integration (e.g., Collective Health partnerships), rising stigma around in-person care, and tech adoption favor its growth, influencing the ecosystem by funding research, normalizing async telehealth, and pressuring legacy providers to digitize.[3][5][6][7] As a female-founded startup in healthcare tech, it exemplifies how VC-backed platforms expand equitable care in a fragmented $50B+ U.S. reproductive health market.[2][4]
Hey Jane is poised for further expansion into stigmatized areas like maternal mental health and more sexual health services, building on 100,000+ patients and research partnerships.[2][3] Trends like AI-driven triage, broader insurance adoption, and federal telehealth policy shifts will amplify its scale, potentially doubling reach amid ongoing restrictions. Its influence may evolve from niche abortion provider to comprehensive virtual reproductive health leader, reshaping access through tech—echoing its origins as a post-Roe lifeline now trusted by thousands.[3][5][6]
Hey Jane has raised $18.3M across 4 funding rounds. Most recently, it raised $6.1M Series A in October 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 19, 2022 | $6.1M Series A | 37 Angels, Amboy Street Ventures, G9 Ventures, Koa Labs, Moving Capital, Portfolia, Social Starts, The Helm, Ulu Ventures | |
| Oct 1, 2022 | $6.0M Venture Round | Ulu Ventures | |
| Aug 26, 2021 | $2.2M Other Equity | FourSight Capital Partners, Gaingels, Koa Labs | |
| Jul 1, 2021 | $4.0M Seed | Awesome People Ventures, Banana Capital, Ali Tamaseb, Electric Capital, First Star Ventures, FJ Labs, Gradient Ventures, Infinite Niches, Khosla Ventures, Paradigm, Precursor Ventures, Social Capital, Adam D'Angelo, Anthony Pompliano, Charlie Feng, Dylan Field, Jen Rubio Butterfield, Julia DeWahl, Scott Belsky, Tonio DeSorrento |